Canaccord Genuity maintained a Buy on Obagi Medical Products (NASDAQ: OMPI) but cut its price target to $15.00 (from $19.00).
This article: 145 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE